Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial

Bryce E. Haac¹, Nathan N. O’Hara²*, Theodore T. Manson², Gerard P. Slobogean², Renan C. Castillo³, Robert V. O’Toole³, Deborah M. Stein¹, on behalf of the ADAPT Investigators

¹ Department of Surgery, R A Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, ² Department of Orthopaedics, R A Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, ³ Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America

¶ Membership of the ADAPT Investigators is provided in the Acknowledgments.

* nohara@som.umaryland.edu

Abstract

Background

Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications. We used a patient-centered weighted composite outcome to globally evaluate aspirin versus low-molecular-weight heparin (LMWH) for VTE prevention in fracture patients.

Methods

We conducted an open-label randomized clinical trial of adult patients admitted to an academic trauma center with an operative extremity fracture, or a pelvis or acetabular fracture. Patients were randomized to receive LMWH (enoxaparin 30-mg) twice daily (n = 164) or aspirin 81-mg twice daily (n = 165). The primary outcome was a composite endpoint of bleeding complications, deep surgical site infection, deep vein thrombosis, pulmonary embolism, and death within 90 days of injury. A Global Rank test and weighted time to event analysis were used to determine the probability of treatment superiority for LMWH, given a 9% patient preference margin for oral administration over skin injections.

Results

Overall, 18 different combinations of outcomes were experienced by patients in the study. Ninety-nine patients in the aspirin group (59.9%) and 98 patients in the LMWH group (59.4%) were event-free within 90 days of injury. Using a Global Rank test, the LMWH had a 50.4% (95% CI, 47.7–53.2%, p = 0.73) probability of treatment superiority over aspirin.
the time to event analysis, LMWH had a 60.5% probability of treatment superiority over aspirin with considerable uncertainty (95% CI, 24.3–88.0%, p = 0.59).

**Conclusion**

The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients. LMWH demonstrated a 60.5% VTE prevention benefit in the weighted time to event analysis. However, this difference did not reach statistical significance and was similar to the elicited patient preferences for aspirin.

**Introduction**

Trauma is a well-described risk factor for venous thromboembolism (VTE) [1–8], but controversy exists regarding the optimal thromboprophylaxis regimen following orthopaedic trauma [9–11]. The Eastern Association for the Surgery of Trauma and the American College of Chest Physicians (ACCP) recommend low-molecular-weight heparin (LMWH) for VTE prophylaxis in trauma patients [11, 12]. However, many orthopaedic trauma surgeons prefer aspirin in light of recent studies suggesting aspirin may be an effective alternative in VTE prevention with a reduced likelihood of bleeding and wound complications [13–19]. As a result, the ACCP guidelines now include aspirin as an option for high-risk orthopaedic surgery patients [11]. To date, most randomized studies comparing these regimens have been conducted in the arthroplasty population. Considering that orthopaedic trauma patients often have multiple injuries that may increase VTE and bleeding risks, drawing inference from the arthroplasty literature is cautioned. Based on the lack of scientific support for various regimens in this population, the Orthopaedic Trauma Association Evidence-Based Quality Value and Safety Committee recently emphasized the need for standardized VTE prevention guidelines to improve care [20].

Like many treatment decisions, determining the optimal thromboprophylaxis regimen for a given patient requires clinicians to weigh the benefits and risks of the available treatment options. Clinical trials traditionally have a separate comparison between the study groups for each study outcome. The analysis technique used in this trial was based on the foundational work by Evans and Follman [21], where the study patient’s experiences are compared between the two treatment groups, allowing multiple outcomes to be counted for a given patient. The clinical relevance of this patient-centered approach can be improved further using composite outcomes that incorporate patient preferences to weigh or rank the plausible outcomes. Techniques, such as a Global Rank test or time to event analysis with weighted, repeated events, can determine the probability of treatment superiority among two or more treatment options [21, 22]. The elicited patient preferences can also be used to determine the preferred treatments under various patient-important thresholds for treatment superiority.

We performed a randomized controlled trial to globally evaluate aspirin versus LMWH for VTE prophylaxis after orthopaedic trauma. In this study, we incorporated several innovative techniques in patient-centered research. Patient preference data was used to weigh the relative importance of the outcomes included our composite endpoint [23], which included bleeding complications, deep surgical site infections, deep vein thrombosis, pulmonary embolism, and death. The patient preference data were also used to set our threshold for a significant difference between the prophylaxis options under the consideration that patients preferred the route of administration for aspirin over the LWMH injections.
Materials and methods

Trial design

The A Different Approach to Preventing Thrombosis (ADAPT) trial was a single-center open-label prospective randomized controlled trial that compared the global benefit of aspirin versus LMWH for orthopaedic trauma patients within 90 days of injury. Global benefit being the synthesis of several patient-important outcomes. Patients were enrolled from January through November 2016 at an academic trauma center in Baltimore, Maryland. Patient follow-up was completed in April 2017. Ethics approval was obtained from the University of Maryland institutional review board (IRB) on September 12, 2015, and informed consent was obtained for all enrolled patients. The trial was registered in clinicaltrials.gov (NCT02774265) on May 17, 2016. Due to an administrative oversight, the trial was registered after patient enrolment was initiated, but prior to the completion of patient enrolment. The authors confirm that all ongoing and related trials for this drug have been registered.

Patient selection

All adult trauma patients admitted with an operative extremity fracture proximal to the carpals or metatarsals, or any hip or acetabular fracture requiring VTE prophylaxis were included in the study. We excluded prisoners, pregnant patients, non-English-speaking patients, patients with an indication for therapeutic anticoagulation or high-dose aspirin (>81 mg daily), and patients receiving pre-existing VTE prophylaxis, therapeutic anticoagulation before admission, or patients that received more than two doses of VTE prophylaxis before consent. Patients with a VTE within the last six months, impaired creatinine clearance (≤30 mL/min), history of heparin-induced thrombocytopenia or aspirin or non-steroidal anti-inflammatory allergy, or another contraindication to receiving a study medication were also excluded. Eligible patients were approached by a member of the research team within 48 hours of admission to the study location and enrolled after obtaining written informed consent.

Randomization

Patients were randomly assigned in a 1:1 ratio to VTE prophylaxis by LMWH or aspirin. Randomization was performed with REDCap, using blocks of six, by research staff at the time of enrollment. The study group allocation was not concealed to the patients, surgeons, or research staff.

Study intervention and procedures

Patients allocated to the LMWH group received 30-mg doses of enoxaparin twice daily with allowance for dose adjustment based on body mass index or anti-factor Xa levels. Patients allocated to the aspirin group received 81-mg doses twice daily. Administration of aspirin was oral, rectal, or via any other form of enteral access. The off-label use of 81-mg aspirin for the indication of VTE prophylaxis was approved by the IRB of record. The duration of prophylaxis was based on hospital guidelines and was dependent on fracture location and weightbearing status. Mechanical prophylaxis with intermittent pneumatic compression devices was ordered as part of the clinical protocol for all inpatients. Study follow-up was conducted 90 days after fracture either at the patient’s clinic appointment or by phone. A chart review was conducted at that time to ensure that no events were missed in the patient review. All prophylaxis doses were monitored daily during the index admission by the study’s research staff. Additionally, medication adherence was assessed at all clinical follow-up visits.
Aspirin use by patients for reasons other than VTE prophylaxis was also tracked. Medication contamination and unplanned crossover were recorded.

**Study outcomes**

The primary outcome was a composite that included bleeding complications, VTE, deep surgical site infections, and death occurring within 90 days after injury. Bleeding complications were defined as a ≥2 g/dL drop in hemoglobin within a 24-hour period after initiation of the study medication, blood transfusion, gastrointestinal bleeding, surgical site hematoma requiring reoperation, or other bleeding events requiring intervention or after initiation of the prophylaxis regimen. The administration of a blood transfusion was at the discretion of the treating clinician who ordered the transfusion. VTE events included pulmonary embolism (PE) defined as either massive, submassive, or clinically significant PE, and clinically significant deep vein thrombosis (DVT) occurring after initiation of the prophylaxis regimen. No screening of asymptomatic patients for VTE events was conducted. Massive and submassive PE were defined using the American Heart Association definitions [24]. Clinically significant PE was defined as symptomatic PE that did not fit massive or submassive criteria. Clinically significant DVT was defined as symptomatic acute thrombus in a deep vein. All VTE events were diagnosed using standard imaging techniques, including angiography, computed tomography angiography, ventilation-perfusion scan, or duplex ultrasonography. Deep surgical site infection (SSI) required a reoperation and was defined based on the Centers for Disease Control and Prevention criteria [25]. All study events were diagnosed and documented by the clinical treating team. All adverse events were reviewed by the Data and Safety Monitoring Board.

**Weighting of study outcomes**

Outcome weights were derived for the study outcomes based on the results of a discrete choice experiment [23]. The experiment surveyed 232 orthopaedic trauma patients to quantify the relative importance of the included endpoints. Using the methods described by Udogwu et al [26], the relative importance of the component outcomes was used to calculate the outcome weights (Table 1) and determined a hierarchy of severity for the observed combination of events experienced during the first 90 days from injury. The weights of the component outcomes are reported relative to death, which has been weighted as 1.00.

**Statistical analysis**

Previous research determined that patients preferred the oral administration of VTE prophylaxis over a subcutaneous injection, assuming the treatment benefits were similar [23]. We then compared the strength of the patients’ route preference with VTE outcome preferences relative to baseline risks. Based on the calculated margins, we determined that patients would be willing to accept a 9% increase in the probability of an adverse event to avoid VTE prophylaxis by skin injection. Therefore, a sample size of 160 patients in each treatment group would

| Component Outcome                                      | Weight |
|--------------------------------------------------------|--------|
| Death                                                  | 1.000  |
| VTE Event (Pulmonary Embolism or Deep Vein Thrombosis)  | 0.055  |
| Deep Surgical Site Infection                           | 0.015  |
| Bleeding Complication                                  | 0.010  |

![Image](https://doi.org/10.1371/journal.pone.0235628.t001)
provide 80% power to detect a 59% treatment superiority, assuming a nonparametric distribution of the weighted outcome and a two-sided alpha of 0.05 [27].

All analyses followed the intention-to-treat principle. We used two techniques to compare the probability of treatment superiority of aspirin with LWMH—a Global Rank test and a weighted time to event analysis. For the Global Rank test, all study outcomes were multiplied by the calculated weight and summed for each patient [28]. Ranks were then assigned to patients so that an event free outcome receives a rank of one. All other combinations of outcomes experienced by patients in the study are ranked based on their cumulative weight. The ranks were compared using a Wilcoxon Rank Sums test. The treatment effect was reported as the Probability Index [29, 30], which is the probability that a randomly selected patient from the aspirin group has a superior outcome rank than a randomly selected patient from the LMWH group. A probability of 50% is considered a null effect.

We also analyzed the data using a time to event model that weighted each event and then adjusted the patient’s health state based on that event for their remaining person-time [26]. Each patient was able to incur an unlimited number of events prior to 90-days post-injury or death, at which point they were censored in the analysis. All patients entered into the study event free. After an event, the remaining person-time that they contributed to the analysis was discounted at one minus the cumulative weight of the events the patient had experienced to that point in time (Fig 1). The treatment effect was reported as the probability of treatment superiority calculated as 1/(1-hazard ratio) [21]. The time to event analysis had 50% power to detect a 59% probability of treatment superiority with a two-sided alpha of 0.05 and the assumption that one-third of the patients would experience at least one study event within 90-days of injury. For patients with incomplete follow-up, last observation carry-forward was used to impute missing outcome weights [31]. We also performed an unweighted analysis comparing the study outcomes between the treatment groups using chi-square tests. The results of the unweighted analyses are available in the supporting information. All analyses were performed using R Version 3.6.1 (Vienna, Austria).

Fig 1. Schematic demonstrating how event-free person-time is weight based on the events experienced by an individual patient.

https://doi.org/10.1371/journal.pone.0235628.g001
Results

Study population

Of the 482 eligible patients, 329 were randomly assigned to receive VTE prophylaxis by LMWH or aspirin (LMWH, n = 164; aspirin, n = 165) (Fig 2). The mean age of the study participants was 47 years (SD, 20 years), and the majority (68%) were male. More than one-third of the participants had a recent history of tobacco use, 10% were diabetic, and 14% were taking daily aspirin before the fracture. Nearly 5% had a history of previous VTE. Most injuries were caused by blunt trauma (96%) to either the lower extremities or pelvis and acetabulum (92%). Nearly one-fourth of the fractures were open, and chest (25%) and head (22%) were common concomitant non-orthopaedic injuries. A full 90-day follow-up was achieved for 93% of the study population. Patient demographics by treatment arm are described in Table 2.

Adherence with assigned intervention

The median time from admission to the initiation of study medication was one day in both treatment arms (aspirin IQR: 0–2; LMWH IQR: 0–1). The medication adherence for
patients allocated to the aspirin arm (94.0%) was not significantly different than patients allocated to LWMH (91.1%, p = 0.18). Patients randomized to aspirin maintained daily prophylaxis significantly longer than those randomized to LMWH (median, 41 versus 26 doses; p<0.01).

Table 2. Baseline patient characteristics (n = 329).

|                          | LMWH (n = 164) | Aspirin (n = 165) |
|--------------------------|---------------|-------------------|
| Age, mean (SD), yr       | 45.4 (20.4)   | 48.0 (18.6)       |
| Sex, n (%)               |               |                   |
| Male                     | 119 (72.6)    | 104 (63.0)        |
| Female                   | 45 (27.4)     | 61 (37.0)         |
| Race, n (%)              |               |                   |
| White                    | 97 (59.5)     | 106 (64.2)        |
| Black                    | 53 (3.3)      | 45 (27.3)         |
| Hispanic                 | 2 (1.2)       | 5 (3.0)           |
| Mixed                    | 6 (3.7)       | 3 (1.8)           |
| Other                    | 5 (3.1)       | 6 (3.6)           |
| Current smoker, n (%)    | 62 (38.3)     | 65 (39.3)         |
| History of venous thromboembolism, n (%) | 7 (4.3) | 8 (4.8) |
| Comorbidities, n (%)     |               |                   |
| Peptic ulcer             | 3 (1.8)       | 12 (7.2)          |
| Diabetes                 | 16 (9.8)      | 17 (10.3)         |
| Active cancer            | 2 (1.2)       | 5 (3.0)           |
| Immunosuppression        | 9 (5.5)       | 8 (4.8)           |
| Additional medications, n (%) |           |                   |
| Aspirin, daily pre-injury| 23 (14.0)     | 22 (13.3)         |
| Plavix, pre-injury       | 2 (1.2)       | 1 (0.6)           |
| Oral contraceptive/estrogen| 3 (1.8) | 3 (1.8)         |
| Body mass index, n (%), kg/m² |         |                   |
| Underweight (<18.5)      | 4 (2.5)       | 6 (3.7)           |
| Normal weight (18.5–24.9) | 57 (35.0) | 57 (35.0)        |
| Overweight (25.0–29.9)   | 53 (32.5)     | 47 (28.8)         |
| Obese (≥30.0)            | 49 (30.1)     | 53 (32.5)         |
| Injury Severity Score, mean (SD) | 11.0 (5.7) | 11.0 (6.6)       |
| Mechanism of injury, n (%) |            |                   |
| Blunt                    | 147 (94.2)    | 148 (97.4)        |
| Penetrating              | 7 (4.5)       | 2 (1.3)           |
| Other                    | 2 (1.3)       | 2 (1.3)           |
| Open fracture, n (%)     | 39 (23.4)     | 37 (22.4)         |
| Fracture location, n (%) |               |                   |
| Upper extremity          | 41 (25.0)     | 42 (25.5)         |
| Lower extremity and pelvis/acetabulum | 149 (90.9) | 154 (93.3)       |
| Multi-limb               | 44 (27.0)     | 43 (26.1)         |
| Non-orthopaedic injury (AIS ≥2), n (%) |          |                   |
| Abdomen                  | 14 (8.5)      | 17 (10.3)         |
| Head                     | 36 (22.0)     | 35 (21.2)         |
| Chest                    | 43 (26.2)     | 39 (23.6)         |

LMWH, low molecular weight heparin; AIS, Abbreviated Injury Scale.

https://doi.org/10.1371/journal.pone.0235628.t002
Twenty-eight (17.0%) patients in the aspirin arm, and 57 (34.8%) patients in the LMWH arm, were administered prophylaxis only during their inpatient admission. Four (2.4%) patients in the aspirin arm and 3 (1.8%) patients in the LMWH arm were on prophylaxis for longer than 28 days.

**Global rank analysis**

Overall, 18 different combinations of outcomes were experienced by patients in the study (Table 3). Ninety-nine patients in the aspirin group (59.9%) and 98 patients in the LMWH group (59.4%) were event-free within 90 days of injury. The cumulative weight of the events was 3.7 in the aspirin group and 2.5 in the LMWH group. Using a Global Rank test, the LMWH had a 50.4% (95% CI, 47.7–53.2%, p = 0.73) probability of treatment superiority over aspirin (Fig 3). Given the patient preference for aspirin [23], the probability of treatment superiority does not meet the 59% LMWH benefit threshold required for patients to change their preference to LMWH.

**Time to event analysis**

In the time to event analysis, the cumulative weighted probability of being event-free at 90-days post-fracture was 97.8% (95% CI, 95.5–1.00%) in the aspirin group and 98.5% (95% CI, 96.6–1.00%) in the LMWH group (Fig 4). LMWH had a 60.5% probability of treatment superiority over aspirin in this analysis but with considerable uncertainty (95% CI, 22.5–88.5%, p = 0.63) given the limited statistical power for this analysis.

**Discussion**

In our primary comparison of aspirin with LMWH, there was no evidence of a significant difference in the probability of VTE prophylaxis superiority for orthopaedic trauma patients. In our time to event analysis, the point estimate for the VTE prophylaxis superiority of LMWH

### Table 3. Outcomes experienced by patients in the study and their assigned weight.

| Rank | Weight | Overall N (%) | ASA N (%) | LMWH N (%) | Event Description |
|------|--------|---------------|-----------|------------|-------------------|
| 1    | 0      | 197 (59.9)    | 99 (60.3) | 98 (59.4)  | Event free        |
| 2    | 0.0099 | 61 (18.5)     | 32 (19.5) | 29 (17.6)  | Bleeding event    |
| 3    | 0.0153 | 16 (4.9)      | 7 (4.3)   | 9 (5.5)    | Deep SSI         |
| 4    | 0.0198 | 21 (6.4)      | 10 (6.1)  | 11 (6.7)   | Two bleeding events |
| 5    | 0.0252 | 7 (2.1)       | 3 (1.8)   | 4 (2.4)    | Deep SSI bleeding event |
| 6    | 0.0351 | 3 (0.9)       | 2 (1.2)   | 1 (0.6)    | Deep SSI, two bleeding events |
| 7    | 0.0398 | 1 (0.3)       | 0 (0.0)   | 1 (0.6)    | Four bleeding events |
| 8    | 0.0548 | 7 (2.1)       | 5 (3.1)   | 2 (1.2)    | VTE               |
| 9    | 0.0647 | 5 (1.5)       | 1 (0.6)   | 4 (2.4)    | VTE, bleeding event |
| 10   | 0.0746 | 1 (0.3)       | 1 (0.6)   | 0 (0.0)    | VTE, two bleeding events |
| 11   | 0.0845 | 2 (0.6)       | 2 (1.2)   | 0 (0.0)    | VTE, three bleeding events |
| 12   | 0.0899 | 1 (0.3)       | 0 (0.0)   | 1 (0.6)    | VTE, deep SSI, two bleeding events |
| 13   | 0.1096 | 1 (0.3)       | 0 (0.0)   | 1 (0.6)    | Two VTEs         |
| 14   | 0.1393 | 1 (0.3)       | 0 (0.0)   | 1 (0.6)    | Two VTEs, three bleeding events |
| 15   | 0.1644 | 1 (0.3)       | 1 (0.6)   | 0 (0.0)    | Three VTEs       |
| 16   | 0.1842 | 1 (0.3)       | 0 (0.0)   | 1 (0.6)    | Three VTEs, two bleeding events |
| 17   | 1.000  | 2 (0.6)       | 0 (0.0)   | 2 (1.2)    | Death            |
| 18   | 1.0198 | 1 (0.3)       | 1 (0.0)   | 0 (0.0)    | Death, two bleeding events |

[https://doi.org/10.1371/journal.pone.0235628.t003](https://doi.org/10.1371/journal.pone.0235628.t003)
exceeded the 59% patient-important threshold. However, this finding was not statistically significant, given the considerable uncertainty around this point estimate.

The ADAPT trial is the first prospective randomized controlled trial to compare the effect of aspirin versus LMWH for VTE prophylaxis in orthopaedic trauma patients. We utilized patient preference data to weight and rank patient-important outcomes to determine the global VTE prophylactic benefit between the two medications [23]. Further, we considered the route of administration for the two medications and calculated a minimal importance threshold based on patients’ preference for oral administration over skin injections [23].

We aimed to describe medication differences under the totality of evidence gained from the trial. Under the ordinal rankings of the Global Rank test, the two medications were nearly indistinguishable in their overall performance. When time from injury was accounted for in the analysis, the probability of VTE prophylaxis superiority for LMWH increased after 45 days.
from injury, when several patients in the aspirin arm sustained subsequent events. Considering the longer median duration of VTE prophylaxis in the aspirin arm, the probability of VTE prophylaxis superiority may have diverged further if the duration of prophylaxis was consistent between the two arms.

Our analytic approach has several benefits. The composite outcome synthesizes the risk and benefits of VTE prophylaxis that clinicians and patients must consider when selecting a regimen. Further, the composite outcome included death, which then accounts for competing risks that often distort the interpretation of individual outcomes [21]. Allowing for multiple events for a given patient accounts for the correlation between events, and provides a more accurate representation of the patient experience.

This study had several limitations. The pragmatic nature resulted in some treatment contamination and a significant difference in the duration of prophylaxis. Study participants, clinicians, and research team members were not blinded to the treatment regimen. Lack of blinding and allocation concealment may have led to a treatment bias resulting in a differential threshold for diagnostic testing of study outcomes. However, we did not observe differential rates of diagnostic testing between the treatment groups. The study was a single-center study, which may limit its generalizability. The weights assigned to the study outcomes were derived from a VTE prophylaxis preference study. The bleeding complication weights did not account

Fig 4. Weighted time to event analysis comparing the probability of being event-free within 90 days of injury. This analysis allows for multiple events for a given patient.

https://doi.org/10.1371/journal.pone.0235628.g004
The findings of this randomized trial suggest that LMWH has a null to moderate global benefit for VTE prophylaxis in orthopaedic trauma patients. When considering patient preferences for an oral route of administration over a skin injection, aspirin is preferred based on the Global Rank analysis. The time to event framework suggests that the global VTE prevention benefits of LMWH may exceed the patient preference margin for aspirin. An evaluation of the effectiveness of these medications on specific clinical endpoints will require a considerably larger sample.

Supporting information

S1 File. CONSORT checklist.
(DOC)

S2 File. Study data.
(XLSX)

S3 File. Approved study protocol.
(PDF)

S4 File. Unweighted results. 90-day results using a intention to treat analysis.
(DOCX)

Acknowledgments

The ADAPT Investigators includes the authors listed in the byline, along with Herman Johal (McMaster University), Richard Van Besien, Peter Z. Berger, George B. Reahl, Dimitrius Marninos, Yasmin Degani, Daniel Mascarenhas, Daniel Connelly, Thomas M. Scalea, who are all affiliated with the University of Maryland School of Medicine. Bryce Haac, MD (brycehaac@gmail.com) is the lead author for the study group.

Author Contributions

Conceptualization: Bryce E. Haac, Nathan N. O’Hara, Theodore T. Manson, Gerard P. Slobogean, Renan C. Castillo, Robert V. O’Toole, Deborah M. Stein.

Data curation: Bryce E. Haac, Nathan N. O’Hara, Gerard P. Slobogean, Renan C. Castillo, Robert V. O’Toole, Deborah M. Stein.

Formal analysis: Bryce E. Haac, Nathan N. O’Hara, Gerard P. Slobogean, Renan C. Castillo, Robert V. O’Toole, Deborah M. Stein.

Investigation: Bryce E. Haac, Nathan N. O’Hara, Theodore T. Manson, Gerard P. Slobogean, Renan C. Castillo, Robert V. O’Toole, Deborah M. Stein.

Methodology: Bryce E. Haac, Nathan N. O’Hara, Gerard P. Slobogean, Renan C. Castillo, Robert V. O’Toole, Deborah M. Stein.
Page dimensions: 612.0x792.0

Project administration: Bryce E. Haac, Nathan N. O’Hara, Theodore T. Manson, Gerard P. Slobogean, Renan C. Castillo, Robert V. O’Toole, Deborah M. Stein.

Resources: Bryce E. Haac, Nathan N. O’Hara, Robert V. O’Toole, Deborah M. Stein.

Supervision: Bryce E. Haac, Nathan N. O’Hara, Theodore T. Manson, Gerard P. Slobogean, Robert V. O’Toole, Deborah M. Stein.

Writing – original draft: Bryce E. Haac, Nathan N. O’Hara.

Writing – review & editing: Bryce E. Haac, Nathan N. O’Hara, Theodore T. Manson, Gerard P. Slobogean, Renan C. Castillo, Robert V. O’Toole, Deborah M. Stein.

References

1. Shackford SR, Moser KM. Deep venous thrombosis and pulmonary embolism in trauma patients. J Intensive Care Med. 1988; 3(2):87–98.
2. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994; 331(24):1601–1606. https://doi.org/10.1056/NEJM199412153312401 PMID: 7969340
3. O’Malley KF, Ross SE. Pulmonary embolism in major trauma patients. J Trauma. 1990; 30(6):748–750. https://doi.org/10.1097/00005373-199006000-00018 PMID: 2352304
4. Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism: a clinico-pathological study in injured and burned patients. Br J Surg. 1961; 48:475–489. https://doi.org/10.1002/bjs.1800481203 PMID: 13750445
5. Shackford SR, Davis JW, Hollingsworth-Fridlund P, Brewer NS, Hoyt DB, Mackersie RC. Venous thromboembolism in patients with major trauma. Am J Surg. 1990; 159(4):365–369. https://doi.org/10.1016/s0002-9610(05)81272-3 PMID: 216799
6. Abelseth G, Buckley RE, Pineo GE, Hull R, Rose MS. Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip. J Orthop Trauma. 1996; 10(4):230–235. https://doi.org/10.1097/00005131-199605000-00002 PMID: 8723400
7. Rogers FB. Venous thromboembolism in trauma patients: a review. Surgery. 2001; 130(1):1–12. https://doi.org/10.1067/msy.2001.114558 PMID: 11436005
8. Hak DJ. Prevention of venous thromboembolism in trauma and long bone fractures. Curr Opin Pulm Med. 2001; 7(5):338–343. https://doi.org/10.1097/00005373-200109000-00015 PMID: 11584186
9. Hill J, Treasure T; National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ. 2010; 340:c95. https://doi.org/10.1136/bmj.c95 PMID: 20106887
10. Mont MA, Jacobs JJ, Boggio LN, Bozig KJ, Della Valle CJ, Goodman SB, et al. AAOS. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011; 19(12):768–776. https://doi.org/10.5435/00124635-201112000-00007 PMID: 22134209
11. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(suppl 2):e278S–e325S.
12. Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma. 2002; 53(1):142–164. https://doi.org/10.1097/00005373-200207000-00032 PMID: 12131409
13. Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013; 158(11):800–806. https://doi.org/10.7326/0003-4819-158-11-201306040-00004 PMID: 2372713
14. [no authors listed]. Collaborative overview of randomised trials of antiplatelet therapy: III. reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients: antiplatelet trials’ collaboration. BMJ. 1994; 308(6923):235–246. PMID: 8054013
15. [no authors listed]. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355(9212):1295–1302. PMID: 10776741
16. Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010; 25(7):1053–1060. https://doi.org/10.1016/j.arth.2009.06.021 PMID: 19769434

17. Vulcano E, Gesell M, Esposito A, Ma Y, Mertiovoua SG, Gonzalez Delia Valle A. Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop. 2012; 36(10):1995–2002. https://doi.org/10.1007/s00264-012-1588-4 PMID: 22684546

18. Raphael IJ, Tischier EH, Huang R, Rothman RH, Hozack WJ, Parvisi J. Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty? Clin Orthop Relat Res. 2014; 472(2):482–488. https://doi.org/10.1007/s11999-013-3135-z PMID: 23817755

19. Gehling H, Giannadakis K, Lefering R, Hessmann M, Achenbach S, Gotzen L. Prospective randomized pilot study of ambulatory prevention of thromboembolism: 2 times 500 mg aspirin (ASS) vs. clovisarin 1750 (NMH) [in German]. Unfallchirurg. 1998; 101(1):42–49. https://doi.org/10.1007/s001130050231 PMID: 9522671

20. Sagi HC, Ahn J, Ciesla D, Collinge C, Molina C, Obremskey WT, et al. Orthopaedic Trauma Association Evidence Based Quality Value and Safety Committee. Venous thromboembolism prophylaxis in orthopaedic trauma patients: a survey of OTA member practice patterns and OTA expert panel recommendations. J Orthop Trauma. 2015; 29(10):e355–e362. https://doi.org/10.1097/BOT.0000000000000387 PMID: 26402304

21. Evans SR, Follmann D. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation. Stat Biopharm Res. 2016; 8(4):386–393. https://doi.org/10.1080/19466315.2016.1207561 PMID: 28435515

22. Evans SR, Rubin D, Follmann D, et al. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015; 61(5):800–806. https://doi.org/10.1093/cid/civ495 PMID: 26113652

23. Haac BE, O’Hara NN, Mullins CD, et al. Patient preferences for venous thromboembolism prophylaxis after injury: a discrete choice experiment [published correction appears in BMJ Open. 2017 Dec 22;7(12):e016676corr1]. BMJ Open. 2017; 7(8):e016676. https://doi.org/10.1136/bmjopen-2017-016676 PMID: 28801426

24. Jaff MR, McMurtty MS, Archer SL, Cushman M, Goldenberg N, et al. American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011; 123(16):1788–1830. https://doi.org/10.1161/CIR.0b013e318214914f PMID: 21422387

25. Centers for Disease Control and Prevention. Surgical Site Infection Event—Procedure-Associated Module. January 2020. Available at: https://www.cdc.gov/nhsv/pdfs/pscmanual/9pssicurrent.pdf. Accessed February 9, 2020.

26. Udogwu U, Howe A, Frey K, et al. A Patient-Centered Composite Endpoint Weighting Technique for Orthopaedic Trauma Research. BMC Med Res Methodol. 2020. Accepted. In Press.

27. Noether GE. Sample-size determination for some common nonparametric tests. J Am Stat Assoc 1987; 82:645–7.

28. Ramchandani R, Schoenfeld DA, Finkelstein DM. Global rank tests for multiple, possibly censored, outcomes. Biometrics. 2016; 72(3):926–935. https://doi.org/10.1111/biom.12475 PMID: 26812695

29. Brown PM, Ezekowitz JA. Composite End Points in Clinical Trials of Heart Failure Therapy: How Do We Measure the Effect Size?. Circ Heart Fail. 2017; 10(1):e003222. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003222 PMID: 28077429

30. Acion L, Peterson JJ, Temple S, Arndt S. Probabilistic index; an intuitive non-parametric approach to measuring the size of treatment effects. Stat Med. 2006; 25:591–602. https://doi.org/10.1002/sim.2256 PMID: 16143965

31. Shao J, Zhong B. Last observation carry-forward and last observation analysis. Stat Med. 2003; 22(15):2429–2441. https://doi.org/10.1002/sim.1519 PMID: 12872300